Sources and References

Primary texts — Peppas, N.A. and Narasimhan, B. (eds.), Nanomedicine: Design and Applications of Magnetic Nanomaterials, Nanosensors and Nanosystems, Wiley, 2018; Torchilin, V. (ed.), Handbook of Nanobiomedical Research, World Scientific, 2014.

Supplementary texts — Saltzman, W.M., Drug Delivery: Engineering Principles for Drug Therapy, Oxford, 2001; Shargel, L., Wu-Pong, S., and Yu, A.B.C., Applied Biopharmaceutics and Pharmacokinetics, 7th ed., McGraw-Hill, 2015.

Online resources — MIT OCW 20.462J “Molecular Principles of Biomaterials”; NIH/NCI nanotechnology characterization laboratory (NCL) public assay cascade; FDA Guidance for Industry: Liposome Drug Products; ICH Q8/Q9/Q10 on pharmaceutical quality.

Chapter 1: Nanoscale Biomedical Engineering

1.1 Why Nanoscale?

Materials at scales of 1–100 nm exhibit behavior that neither molecular nor bulk descriptions capture. Nanoparticles share length scales with proteins (5–10 nm), viruses (20–200 nm), and organelles (0.1–10 µm); they can circulate through vasculature (capillary diameter 5–10 µm), extravasate through tumor fenestrations, and cross selected biological barriers. Surface-to-volume ratios at the nanoscale enable high binding valency and chemistry.

1.2 Biomedical Engineering Primer

Nanomedicine sits at the intersection of materials science, pharmacology, immunology, and chemical engineering. The engineer designs: the material platform (polymer, lipid, inorganic, biological), the payload (drug, gene, imaging agent), the targeting strategy (passive EPR, active ligand-receptor), the release mechanism (diffusion, degradation, stimulus-responsive), and the manufacturing process (scalable, reproducible, sterile).

1.3 Regulatory and Development Pathway

From lab to clinic: preclinical (in vitro, in vivo), IND filing, Phase I (safety, 20-80 subjects), Phase II (efficacy, 100-300), Phase III (pivotal, 1000+), NDA/BLA. Nanomedicines face specific regulatory questions around characterization, reproducibility, and complex biology—FDA and EMA issue product-specific guidances (liposomes, iron-carbohydrate complexes).

Chapter 2: Nanoparticle Platforms

2.1 Liposomes

Phospholipid bilayer vesicles self-assemble from amphiphile hydration. Unilamellar (SUV, 20-100 nm; LUV, 100-1000 nm) vs. multilamellar. Hydrophilic drugs load into the aqueous core; hydrophobic drugs partition into the bilayer. PEGylation (poly(ethylene glycol) surface modification) suppresses opsonization and extends circulation. Doxil (liposomal doxorubicin) was the first approved nanodrug (1995).

2.2 Lipid Nanoparticles

Ionizable lipids (DLin-MC3-DMA, SM-102, ALC-0315) electrostatically encapsulate mRNA or siRNA at acidic pH, endosomally escape via proton sponge and fusion. mRNA-LNPs underpin the COVID-19 vaccines and advance into therapeutic protein replacement (Patisiran for hereditary transthyretin amyloidosis).

2.3 Polymeric Nanoparticles

PLGA, PLA, and PCL are biodegradable polyesters; PLGA degrades by hydrolysis to lactic and glycolic acid over weeks to months. Nanoprecipitation (flash nanoprecipitation, microfluidic mixing) and emulsion-solvent evaporation produce 50-200 nm particles with tunable release profiles. Abraxane (albumin-paclitaxel nanoparticles) typifies protein-based platforms.

2.4 Inorganic Nanoparticles

Iron oxide (MRI contrast, hyperthermia), gold (photothermal, radiosensitizer, SERS sensing), silica (mesoporous for high payload), quantum dots (imaging, though toxicity limits clinical use). Feraheme (ferumoxytol) is clinically used for iron deficiency.

2.5 Dendrimers and Micelles

Dendrimers (PAMAM, poly(ester)) are monodisperse branched macromolecules with surface groups for functionalization. Block copolymer micelles (PEG-b-PLA, PEG-b-PLGA) self-assemble above CMC; core loads hydrophobic drugs.

Chapter 3: Pharmacokinetics and Biodistribution

3.1 ADME Framework

Absorption, distribution, metabolism, excretion. For parenteral nanomedicines, distribution and elimination dominate. Clearance \( CL \) [mL/min] relates dose rate to steady-state concentration:

Volume of distribution \( V_d = \text{Dose}/C_0 \). Half-life \( t_{1/2} = 0.693 V_d/CL \).

3.2 Compartmental Models

One-compartment: \( dC/dt = -k C \), \( C = C_0 e^{-kt} \). Two-compartment (central + peripheral) captures distribution phase. Nanoparticles often show biphasic or multiphasic kinetics because clearance differs from plasma drug.

3.3 MPS Clearance

Mononuclear phagocyte system (liver Kupffer cells, spleen macrophages) uptakes circulating particles via opsonin recognition. PEGylation, zwitterionic coatings, and CD47-mimicking “self” peptides reduce uptake. Glomerular filtration removes particles < 5-6 nm hydrodynamic diameter (below renal cutoff).

3.4 Toxicity

Acute (complement activation-related pseudoallergy, cytokine release), chronic (accumulation in reticuloendothelial system), immune (antibody response to PEG, to protein coronas). Nanoparticle toxicity requires dedicated characterization beyond small-molecule paradigms: NCL assay cascade and 21 CFR and ICH M3(R2) guidelines apply.

Chapter 4: Targeted Delivery

4.1 Passive vs. Active Targeting

Passive: rely on biological features (EPR, lung first-pass capture, mucosal retention). Active: surface-conjugated ligands bind receptors (folate, transferrin, RGD for integrins, antibodies, aptamers). Active targeting adds binding affinity but rarely changes biodistribution at the organ level; its clinical translation has been challenging.

4.2 Stimulus-Responsive Release

pH (endosomal acidification), redox (glutathione in cytosol), enzyme (MMP, cathepsin in tumor stroma), temperature (LCST polymers, poly(N-isopropylacrylamide)), magnetic (superparamagnetic iron oxide with alternating field), light (photothermal, photodynamic, photochemical). Each couples a stimulus-responsive chemistry to payload release or particle disassembly.

4.3 Crossing Barriers

Blood-brain barrier (tight junctions, efflux pumps): receptor-mediated transcytosis via transferrin, insulin, LRP1 ligands; transient opening by focused ultrasound plus microbubbles. Mucosal barriers (GI tract, lung): mucus-penetrating particles with dense PEG coatings. Stratum corneum (skin): microneedles, iontophoresis.

4.4 Intracellular Trafficking

Endocytosis (clathrin, caveolae, macropinocytosis) routes particles to endosomes. Escaping endosomal degradation is crucial for nucleic acid delivery: proton sponge mechanism (PEI, ionizable lipids), pH-responsive membrane-active peptides (GALA, melittin), photochemical internalization.

Chapter 5: Drug Delivery Strategies

5.1 Routes of Administration

• IV infusion: direct plasma access, rapid onset; highest systemic exposure.
• Subcutaneous/intramuscular: depot formation, sustained release; easier self-administration.
• Oral: convenience but first-pass metabolism and GI barriers; enteric coatings, mucoadhesive systems.
• Pulmonary: lung delivery for respiratory disease and systemic absorption via alveolar surface.
• Transdermal: patches, microneedles; bypass first-pass.
• Intranasal, ocular, intrathecal: targeted local delivery.

5.2 Controlled Release Kinetics

Diffusion-controlled: Higuchi model for dispersed drug in a matrix: \( Q = \sqrt{2 D C_s (A - C_s) t} \), giving \( t^{1/2} \) release. Erosion-controlled: polymer degradation releases drug; zero-order possible for reservoir devices.

Weibull, first-order, Korsmeyer-Peppas, and mechanistic models fit in vitro release profiles. In vitro-in vivo correlation (IVIVC) links dissolution tests to human pharmacokinetics.

5.3 Biopharmaceutical and Pharmaceutical Industries

Biopharmaceuticals (proteins, peptides, mRNA) demand gentle processing to preserve biological activity: cold-chain, avoidance of shear and interfaces, stabilizers (sugars, surfactants), lyophilization. Pharmaceutical industries (small molecules) use traditional unit operations: tablet compression, encapsulation, coating, sterile manufacturing.

5.4 Formulation Science

Solubility enhancement (co-solvents, cyclodextrins, solid dispersions, nanosuspensions), stability (antioxidants, chelators, pH buffers), preservation (antimicrobials), manufacturability (flow, compressibility). Quality by Design (ICH Q8) enforces a systematic mapping of critical quality attributes to critical process parameters.

Chapter 6: Manufacturing and Quality Control

6.1 Nanoparticle Manufacturing

Batch methods (high-shear homogenization, ultrasonication, solvent evaporation) and continuous methods (microfluidic mixing, flash nanoprecipitation, static-mixer formulation) yield different size distributions and scale behaviors. Microfluidics produces LNPs for mRNA vaccines at multi-liter per hour scale with tight PDI.

6.2 Characterization

Size and distribution: DLS, nanoparticle tracking analysis, cryo-TEM, AUC. Zeta potential (DLS with electrophoresis). Encapsulation efficiency: HPLC assay of loaded/free drug. Surface composition: XPS, SPR. Stability: accelerated (elevated temperature, freeze-thaw, mechanical agitation).

6.3 Sterility and Endotoxin

Parenteral products must be sterile and pyrogen-free. Terminal sterilization (autoclave, gamma) may degrade nanoparticles; sterile filtration (0.22 µm) works only for particles < 200 nm and is followed by aseptic fill. Endotoxin assays (LAL) ensure compliance with USP < 85 > (typically < 0.5 EU/mL for parenteral).

6.4 Regulatory Chemistry, Manufacturing, and Controls (CMC)

CMC dossiers describe product and process: API characterization, excipient qualification, manufacturing flowcharts with in-process controls, analytical method validation (ICH Q2(R2)), stability testing (ICH Q1A), drug product specifications, and container-closure integrity. Nanoparticle drugs often require bespoke analytical methods for size, composition, drug release, and functional biology.